Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: The sooner the better

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 503-510

  Petrelli, Fausto ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Adjuvant chemotherapy; Adjuvant trastuzumab; Breast cancer; Concomitant; Sequential

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; COMPARATIVE STUDY; DRUG ADMINISTRATION; FEMALE; MORTALITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84866285648     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9897-9     Document Type: Article

References (28)

1. Perez, EA, Suman, VJ, Davidson, NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 Weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Cancer Res 2009;69:(abstr 80).
2. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831, NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2- positive breast cancer (abstract). J Clin Oncol. 2007;25:6s.
3. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Cancer Res. 2009;69: 500s. abstr 62.
4. Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009;27(36):6129-34.
5. Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27(34): 5685-92.
6. Gianni L, Goldhirsch A, Gelber RD, et al. Update of the HERA trial and the role of 1 year trastuzumab as adjuvant therapy for breast cancer. Breast. 2009;18(Supplement 1):S11. Abstr S25.
7. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin, cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811.
8. Rastogi P, Jeong J, Geyer CE, et al. Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)-paclitaxel compared to AC-T with trastuzumab (abstract). J Clin Oncol. 2007;25:6s.
9. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231-8.
10. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab, paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype, gene amplification. J Clin Oncol. 2001;19:2587.
11. Gori S, Colozza M, Mosconi AM, et al. Phase II study of weekly paclitaxel, trastuzumab in anthracycline-and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer. 2004;90:36.
12. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab, vinorelbine or taxane study. Cancer. 2007;110:965.
13. Vogel CL, Tan-Chiu E. Trastuzumab plus chemotherapy: convincing survival benefit or not? J Clin Oncol. 2005;23:4247.
14. Esteva FJ, Valero V, Booser D, et al. Phase IIstudy of weekly docetaxel, trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:1800.
15. Montemurro F, Choa G, Faggiuolo R, et al. Safety, activity of docetaxel, trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study. Am J Clin Oncol. 2003;26:95.
16. Tedesco KL, Thor AD, Johnson DH, et al. Docetaxel combined with trastuzumab is an active regimen in her-2 3+ overexpressing, fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase ii trial. J Clin Oncol. 2004;22: 1071.
17. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase ii trial of the efficacy, safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265.
18. Raff JP, Rajdev L, Malik U, et al. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer. 2004;4:420.
19. Bontenbal M, Seynaeve C, Stouthard J et al. Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastzumab/docetaxel as first-line chemotherapy in Her2-neu positive, metastatic breast cancer (HERTAX study) (Abstract). J Clin Oncol 2008;26:44s. (Abstract available online at www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts+&vmview=abst-detail-view&confID= 55&abstractID=34668, Accessed 17 July 2008).
20. Inoue K, Nakagami K, Mizutani M, et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat. 2010;119:127.
21. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26:44.
22. Pegram MD, Konecny GE, O'Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004;96:739.
23. Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification, response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst. 2004;96:1141.
24. Di Leo A, Chan S, Paesmans M, et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or singleagent docetaxel. Breast Cancer Res Treat. 2004;86:197.
25. Muller V, Witzel I, Luck HJ, et al. Prognostic, predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat. 2004;86:9.
26. Sjostrom J, Collan J, von Boguslawski K, et al. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate, 5-fluorouracil in advanced breast cancer. Eur J Cancer. 2002;38:535.
27. Hayes DF, Thor AD, Dressler LG, et al. HER2, response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007; 357:1496.
28. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson cancer center experience. J Clin Oncol. 2006;24:4107.